Abstract
Abstract Background ABBV-181 is a monoclonal antibody that binds to cell surface programmed cell death 1 (PD-1). Dose-finding data have been previously reported (Powderly et al, Ann Oncol 2018). This report summarizes ABBV-181 monotherapy data from Japanese (JPN) and cohort-matched Western (WST) patients (pts) enrolled in the first-in-human study evaluating ABBV-181 in pts with previously treated advanced solid tumors (NCT03000257). Methods Pts received ABBV-181 in a 3 + 3 dose-escalation design at 1, 3, and 10 mg/kg IV every 2 weeks (Q2W) until progression (JPN pts: 3 and 10 mg/kg only) and a basket expansion cohort at a recommended phase 2 dose (RP2D). Response was assessed Q8W per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 and immune RECIST. Serial pharmacokinetic (PK) and pharmacodynamic samples were collected. Results As of Nov 2018, 56 pts (JPN: 11) were enrolled (total and JPN pts, median days on treatment [range], 1 mg/kg: 12, 120 [43-653]; 3 mg/kg: 10 and 4, 64 [1-134] and 29 [15-106]; 10 mg/kg: 11 and 4, 64 [1-225] and 29 [1-85]; basket: 23 and 3, 29 [1-353] and 15 [15-16]). Adverse events (AEs) were reported in (total, JPN pts): 10, 4 (3 mg/kg); 10, 3 (10 mg/kg); and 22, 2 (basket), with 5, 1 (3 mg/kg); 4, 0 (10 mg/kg); and 15, 1 (basket) pts having Grade (G)≥3 AEs. No dose-limiting toxicities or drug-related G5 AEs were reported. The most common G ≥ 1 AEs in JPN pts were (%): pyrexia (36), anemia (27), constipation (18); G ≥ 3 AEs were: anemia, decreased appetite, progression (9% each, all unrelated to ABBV-181). One G5 AE of progression was reported. Seven of 11 JPN pts discontinued ABBV-181 (all for disease progression). ABBV-181 PK appears dose-proportional and comparable in JPN and WST pts. ABBV-181 led to complete PD-1 receptor occupancy, similar kinetics of cytokine induction, and transient T-cell changes in JPN and WST pts. Conclusion These results support a RP2D of 250 mg Q2W, 375 mg Q3W, or 500 mg Q4W in both JPN and WST pts.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.